|
1
|
Rosca MG, Tandler B and Hoppel CL:
Mitochondria in cardiac hypertrophy and heart failure. J Mol Cell
Cardiol. 55:31–41. 2013. View Article : Google Scholar :
|
|
2
|
Foryst-Ludwig A and Kintscher U: Sex
differences in exercise-induced cardiac hypertrophy. Pflugers Arch.
465:731–737. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Abel ED and Doenst T: Mitochondrial
adaptations to physiological vs. pathological cardiac hypertrophy.
Cardiovasc Res. 90:234–242. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hou J and Kang Y: Regression of
Pathological Cardiac Hypertrophy: Signaling pathways and
therapeutic targets. Pharmacol Ther. 135:337–354. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Pillai VB, Sundaresan N and Gupta MP:
Regulation of Akt signaling by sirtuins: Its implication in cardiac
hypertrophy and aging. Circ Res. 114:368–378. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Creemers EE and Pinto Y: Molecular
mechanisms that control interstitial fibrosis in the
pressure-overloaded heart. Cardiovasc Res. 89:265–272. 2011.
View Article : Google Scholar
|
|
7
|
Oka T, Akazawa H, Naito AT and Komuro I:
Angiogenesis and cardiac hypertrophy: Maintenance of cardiac
function and causative roles in heart failure. Circ Res.
114:565–571. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Liu ZHJ, Hu R, Huo Y, Gong J, Zhang Y, Wei
C and Pu J: Gene expression profile of increased heart rate in
shensongyangxin-treated bradycardia rabbits. Evid Based Complement
Alternat Med. 2014:7159372014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Liu Y, Li N, Jia Z, Lu F and Pu J: Chinese
medicine shensongyangxin is effective for patients with
bradycardia: Results of a randomized, double-blind,
placebo-controlled multicenter trial. Evid Based Complement
Alternat Med. 2014:6057142014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wang AH, Pu JL, Qi XY, Miao WL, Hou ZS,
Cong HL, Zhou JZ, Liu XF, Li SM and Han QH: Evaluation of
shensongyangxin capsules in the treatment of paroxysmal atrial
fibrillation: A randomized, double-blind and controlled multicenter
trial. Zhonghua Yi Xue Za Zhi. 91:1677–1681. 2011.In Chinese.
PubMed/NCBI
|
|
11
|
Zou JG, Zhang J, Jia ZH and Cao KJ:
Evaluation of the traditional Chinese Medicine Shensongyangxin
capsule on treating premature ventricular contractions: A
randomized, double-blind, controlled multicenter trial. Chin Med J
(Engl). 124:76–83. 2011.
|
|
12
|
Yang Z, Yu X and Yu ML: Effects of
shensongyangxin capsule on heart rate turbulence and heart rate
variability in chronic heart failure. Chin Med J (Engl).
126:4389–4391. 2013.
|
|
13
|
Chai S, Wang S, Yao L, Wu A, Liu Y and Rao
C: Effect of shensongyangxin capsule on myocardial remodeling and
ventricular fibrillation threshold value in rat with coronary
artery ligation. Zhongguo Zhong Yao Za Zhi. 34:2101–2104. 2009.In
Chinese. PubMed/NCBI
|
|
14
|
Yuan Y, Zong J, Zhou H, Bian ZY, Deng W,
Dai J, Gan HW, Yang Z, Li H and Tang QZ: Puerarin attenuates
pressure overload-induced cardiac hypertrophy. J Cardiol. 63:73–81.
2014. View Article : Google Scholar
|
|
15
|
Yan L, Wei X, Tang QZ, Feng J, Zhang Y,
Liu C, Bian ZY, Zhang LF, Chen M, Bai X, et al: Cardiac-specific
mindin overexpression attenuates cardiac hypertrophy via blocking
AKT/GSK3β and TGF-β1-Smad signalling. Cardiovasc Res. 92:85–94.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Aoyagi T and Matsui T: Phosphoinositide-3
kinase signaling in cardiac hypertrophy and heart failure. Curr
Pharm Des. 17:1818–1824. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Skurk C, Izymiya Y, Maatz H, Razeghi P,
Shiojima I, Sandri M, Sato K, Zeng L, Schiekofer S, Pimentel D, et
al: The FOXO3a transcription factor regulates cardiac myocyte size
downstream of AKT signaling. J Biol Chem. 280:20814–20823. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yu W, Chen C, Fu Y, Wang X and Wang W:
Insulin signaling: A possible pathogenesis of cardiac hypertrophy.
Cardiovasc Ther. 28:101–105. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wu QQ, Zonj J, Gao L, Dai J, Yang Z, Xu M,
Fang Y, Ma ZG and Tang QZ: Sulforaphane protects H9c2
cardiomyocytes from angiotensin II-induced hypertrophy. Herz.
39:390–396. 2014. View Article : Google Scholar
|
|
20
|
Maillet M, van Berlo JH and Molkentin JD:
Molecular basis of physiological heart growth: Fundamental concepts
and new players. Nat Rev Mol Cell Biol. 14:38–48. 2013. View Article : Google Scholar
|
|
21
|
Ni YG, Berenji K, Wang N, Oh M, Sachan N,
Dey A, Cheng J, Lu G, Morris DJ, Castrillon DH, et al: FOXo
transcription factors blunt cardiac hypertrophy by inhibiting
calcineurin signaling. Circulation. 114:1159–1168. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Edgley AJ, Krum H and Kelly DJ: Targeting
fibrosis for the treatment of heart failure: A role for
transforming growth factor-β. Cardiovasc Ther. 30:e30–40. 2014.
View Article : Google Scholar
|
|
23
|
Kamato D, Burch M, Piva TJ, Rezaei HB,
Rostam MA, Xu S, Zheng W, Little PJ and Osman N: Transforming
growth factor-β signalling: Role and consequences of Smad linker
region phosphorylation. Cell Signal. 25:2017–2024. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Szabó Z, Magga J, Alakoski T, Ulvila J,
Piuhola J, Vainio L, Kivirikko KI, Vuolteenaho O, Ruskoaho H,
Lipson KE, et al: Connective tissue growth factor inhibition
attenuates left ventricular remodeling and dysfunction in pressure
overload-induced heart failure. Hypertension. 63:1235–1240. 2014.
View Article : Google Scholar : PubMed/NCBI
|
